BASEL MEDICAL GROUP LTD (BMGL) Fundamental Analysis & Valuation
NASDAQ:BMGL • VGG0864B1031
Current stock price
0.5951 USD
-0.02 (-3.08%)
Last:
This BMGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BMGL Profitability Analysis
1.1 Basic Checks
- In the past year BMGL has reported negative net income.
- BMGL had a negative operating cash flow in the past year.
1.2 Ratios
- BMGL has a worse Return On Assets (-73.60%) than 90.00% of its industry peers.
- BMGL has a Return On Equity of -255.19%. This is in the lower half of the industry: BMGL underperforms 79.00% of its industry peers.
- With an excellent Return On Invested Capital value of 10.26%, BMGL belongs to the best of the industry, outperforming 81.00% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BMGL is significantly above the industry average of 8.63%.
- The 3 year average ROIC (22.16%) for BMGL is well above the current ROIC(10.26%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.6% | ||
| ROE | -255.19% | ||
| ROIC | 10.26% |
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
1.3 Margins
- BMGL has a Operating Margin (4.53%) which is in line with its industry peers.
- In the last couple of years the Operating Margin of BMGL has declined.
- The Profit Margin and Gross Margin are not available for BMGL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.53% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. BMGL Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BMGL is creating value.
- The number of shares outstanding for BMGL has been increased compared to 1 year ago.
- BMGL has a better debt/assets ratio than last year.
2.2 Solvency
- BMGL has an Altman-Z score of -0.39. This is a bad value and indicates that BMGL is not financially healthy and even has some risk of bankruptcy.
- BMGL has a Altman-Z score of -0.39. This is amonst the worse of the industry: BMGL underperforms 81.00% of its industry peers.
- A Debt/Equity ratio of 0.28 indicates that BMGL is not too dependend on debt financing.
- BMGL has a better Debt to Equity ratio (0.28) than 67.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.39 |
ROIC/WACC0.93
WACC11.03%
2.3 Liquidity
- BMGL has a Current Ratio of 1.23. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
- BMGL's Current ratio of 1.23 is in line compared to the rest of the industry. BMGL outperforms 44.00% of its industry peers.
- A Quick Ratio of 1.19 indicates that BMGL should not have too much problems paying its short term obligations.
- BMGL's Quick ratio of 1.19 is in line compared to the rest of the industry. BMGL outperforms 51.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.19 |
3. BMGL Growth Analysis
3.1 Past
- The earnings per share for BMGL have decreased strongly by -458.69% in the last year.
- The Revenue has grown by 8.02% in the past year. This is quite good.
- BMGL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.03% yearly.
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BMGL Valuation Analysis
4.1 Price/Earnings Ratio
- BMGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 99.00% of the companies in the same industry are more expensive than BMGL, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.59 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BMGL Dividend Analysis
5.1 Amount
- BMGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BMGL Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:BMGL (4/2/2026, 8:10:13 PM)
0.5951
-0.02 (-3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.18M
Revenue(TTM)16.35M
Net Income(TTM)-12.40M
AnalystsN/A
Price TargetN/A
Short Float %1.33%
Short Ratio3.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.96 | ||
| P/tB | 2.96 | ||
| EV/EBITDA | 0.59 |
EPS(TTM)-0.51
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.68
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.6% | ||
| ROE | -255.19% | ||
| ROCE | 12.02% | ||
| ROIC | 10.26% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.53% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)33.64%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.71 | ||
| Cap/Depr | 4.64% | ||
| Cap/Sales | 0.34% | ||
| Interest Coverage | 1.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | -0.39 |
F-Score3
WACC11.03%
ROIC/WACC0.93
Cap/Depr(3y)2.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.21%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.22%
EBIT growth 3Y-60.44%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-275.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-273.12%
OCF growth 3YN/A
OCF growth 5YN/A
BASEL MEDICAL GROUP LTD / BMGL Fundamental Analysis FAQ
What is the fundamental rating for BMGL stock?
ChartMill assigns a fundamental rating of 2 / 10 to BMGL.
What is the valuation status for BMGL stock?
ChartMill assigns a valuation rating of 1 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.
Can you provide the profitability details for BASEL MEDICAL GROUP LTD?
BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 2 / 10.